Deleveraging Progress Offset by Persistent GAAP Losses
Elanco's total debt has fallen from $5.7B in 2024Q2 to $3.7B in 2026Q3, and its debt-to-equity ratio improved from 0.96 to 0.56, suggesting meaningful balance sheet repair is underway.
Revenue growth slowed to 11.3% in 2026Q3 while operating margin compressed to 6.4% from 22.4% in 2026Q1, suggesting operating income is not yet scaling with a gross margin that has recovered to roughly 57%.
Analyst Consensus-0.1% target
Buy(22 analysts)
15 Buy5 Hold2 Sell
The Bull Case
Upside Catalysts
Strong quarterly results
Elanco's latest quarterly results and initial 2026 guidance have improved investor sentiment, highlighting operational execution and margin expansion.
Market leadership position
Elanco is the second largest independent animal health player in a growing market, with a strong presence in both farm animals and pets.
Innovative product pipeline
The company has a late-stage pipeline with potential blockbuster products expected to launch in large market spaces, driving future growth.
Elanco Animal Health Incorporated ( ELAN ) 2026 UBS Global Healthcare Conference November 9, 2026 1:15 PM EST Company Participants Robert VanHimbergen - Executive VP & CFO Rajeev Modi - Executive Vice President of U.S. Pet Health & Global Digital Transformation Conference Call Participants Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Presentation Andrea Zayco Narvaez Alfonso UBS Investment Bank, Research Division So good afternoon, everybody. I'm Andrea Alfonso.
Elanco Animal Health NYSE: ELAN raised its full-year outlook after third-quarter revenue rose 11%, driven by demand for its pet health products Zenrelia and Credelio Quattro and higher prices across its portfolio.
Elanco Animal Health Incorporated ( ELAN ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Tiffany Kanaga - VP of Investor Relations & ESG Jeffrey Simmons - President, CEO & Director Robert VanHimbergen - Executive VP & CFO Conference Call Participants Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Glen Santangelo - Barclays Bank PLC, Research Division Matthew Dellatorre - Goldman Sachs Group, Inc., Research Division Erin Wilson Wright - Morgan Stanley, Research Division Umer Raffat - Evercore ISI Institutional Equities, Research Division Brandon Vazquez - William Blair & Company L.L.C., Research Division Andrea Zayco Narvaez Alfonso - UBS Investment Bank, Research Division Navann Ty Dietschi - BNP Paribas, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Steven Dechert - KeyBanc Capital Markets Inc., Research Division Christopher LoBianco - TD Cowen, Research Division Presentation Operator Good day, and welcome to Elanco Animal Health Reports Third Quarter 2026 Results.
Filtered for Elanco Animal Health IncorporatedMore Headlines
04
Compare before deciding
Benchmark ELAN against direct peers instead of judging its metrics in isolation.
Peers Comparison
Key metrics vs top competitors for Elanco Animal Health Incorporated (ELAN)
What is Elanco Animal Health Incorporated's revenue?
Elanco Animal Health Incorporated (ELAN) reported $5.15B in revenue over the trailing twelve months. Revenue was $4.71B in fiscal year 2025. That is 62% more than the $2.91B of fiscal year 2016.
How fast is Elanco Animal Health Incorporated growing?
Elanco Animal Health Incorporated (ELAN) grew revenue by 12.1% over the trailing twelve months, compared with the twelve months before.
Is ELAN profitable?
No. Elanco Animal Health Incorporated (ELAN) reported a net loss of $147.0M over the trailing twelve months.
Dividend & Returns
What is ELAN's return on equity?
Elanco Animal Health Incorporated (ELAN) had a return on equity (ROE) of -2.2% over the trailing twelve months. A negative ROE means the company lost money over the period.
What is Elanco Animal Health Incorporated's free cash flow?
Elanco Animal Health Incorporated (ELAN) generated $408.0M in free cash flow over the trailing twelve months.